Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Chemotherapy or radiotherapy within 4 weeks prior to entering the study
• •Receiving any other study agents
• •CNS lymphoma requiring active therapy
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to imatinib mesylate
• •Participants requiring concomitant administration of any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible
• •Patient previously received radiotherapy to 25% or greater of the bone marrow
• •Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Pregnant or lactating women
• •History of a different malignancy except for individuals who have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy
• •HIV-positive individuals on combination antiretroviral therapy
• •Known chronic liver disease
• •Major surgery within 2 weeks prior to study entry